Literature DB >> 18695430

Possible heart failure exacerbation associated with pregabalin: case discussion and literature review.

Robert Lee Page1, Mona Cantu, JoAnn Lindenfeld, Lawrence J Hergott, Brian D Lowes.   

Abstract

Pregabalin is an analog of the neurotransmitter gamma-aminobutyric acid that exhibits analgesic, anticonvulsant, and anxiolytic properties. Owing to its pharmacologic properties, the drug has been used worldwide in the management of diabetic peripheral neuropathy, postherpetic neuralgia, generalized anxiety disorder, and social anxiety disorder. Although central nervous system disturbances account for the majority of pregabalin's side effects, dose-dependent peripheral edema and weight gain have also been reported. Recently, three case reports have been published documenting a possible association between pregabalin administration and chronic heart failure decompensation. We present three additional cases of possible heart failure exacerbation in patients with clinically stable heart failure who received pregabalin for neuropathic pain. Additionally, we review the literature addressing the nature and possible etiology for this adverse effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695430     DOI: 10.2459/JCM.0b013e3282fb7629

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  10 in total

1.  Peripheral edema with pregabalin.

Authors:  Romayne Gallagher; Nicole Apostle
Journal:  CMAJ       Date:  2012-11-05       Impact factor: 8.262

Review 2.  Treatment considerations for patients with neuropathic pain and other medical comorbidities.

Authors:  Maija L Haanpää; Geoffrey K Gourlay; Joel L Kent; Christine Miaskowski; Srinivasa N Raja; Kenneth E Schmader; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

Review 3.  Symptom management challenges in heart failure: pharmacotherapy considerations.

Authors:  Diana Stewart; Mary Lynn McPherson
Journal:  Heart Fail Rev       Date:  2017-09       Impact factor: 4.214

4.  Pregbalin induced recurrent syncopal attacks with prolong QT interval.

Authors:  Adem Adar; Fahri Cakan; Orhan Önalan
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-08-30       Impact factor: 1.468

Review 5.  WITHDRAWN: Anticonvulsants for fibromyalgia.

Authors:  Nurcan Üçeyler; Claudia Sommer; Brian Walitt; Winfried Häuser
Journal:  Cochrane Database Syst Rev       Date:  2017-10-09

6.  Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure.

Authors:  Christie A Schumacher; Elizabeth K Van Dril; Kayce M Shealy; Jennifer D Goldman
Journal:  Clin Diabetes       Date:  2021-01

7.  Risk of heart failure and edema associated with the use of pregabalin: a systematic review.

Authors:  Joanne M Ho; Andrea C Tricco; Laure Perrier; Maggie Chen; David N Juurlink; Sharon E Straus
Journal:  Syst Rev       Date:  2013-05-04

Review 8.  Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia.

Authors:  Santosh Bhusal; Sherilyn Diomampo; Marina N Magrey
Journal:  Drug Healthc Patient Saf       Date:  2016-02-17

9.  A Case Report of Syndrome of Inappropriate Antidiuretic Hormone Induced by Pregabalin.

Authors:  Youn Joo Jung; Dong-Young Lee; Hae Won Kim; Hyun Sun Park; Beom Kim
Journal:  Electrolyte Blood Press       Date:  2016-12-31

10.  Pregabalin as a probable cause of central serous chorioretinopathy: Two case reports.

Authors:  Yusuf Emre Doğan; Kübra Neslihan Kurt Oktay; Yelda Buyru Özkurt; İlknur Aktaş
Journal:  Turk J Phys Med Rehabil       Date:  2021-12-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.